Literature DB >> 28066860

Is-it possible to distinguish irritable bowel syndrome with constipation from functional constipation?

M Bouchoucha1,2, G Devroede3, C Bon4, B Bejou4, F Mary4, R Benamouzig4.   

Abstract

BACKGROUND: The Rome III criteria classify patients complaining of constipation into two main groups: patients with functional constipation (FC) and patients with constipation predominant irritable bowel syndrome (IBS-C). The purpose of this study was to identify differences in the intensity of symptoms and total and segmental colonic transit time in these two types of patients.
METHODS: We performed a prospective evaluation of 337 outpatients consecutively referred for chronic constipation and classified according to the Rome III criteria as FC or IBS-C. They were asked to report symptom intensity, on a 10-point Likert scale, for diarrhea, constipation, bloating and abdominal pain. Stool form was reported using the Bristol scale, and colonic transit time was measured by using multiple-ingestion single-marker single-film technique. Statistical analysis was completed by a discriminant analysis.
RESULTS: Female gender and obstructed defecation was more frequent in IBS-C patients than in FC patients. IBS-C patients reported greater symptom intensity than FC patients, but stool form, and total and segmental colonic transit time were not different between the two groups. Multivariate logistic regression showed that only two parameters, bloating and abdominal pain, were related to the IBS-C or to the FC phenotype, and discriminant analysis showed that these two parameters were sufficient to give a correct classification of 71% of the patients.
CONCLUSIONS: Our study suggests that self-evaluation of abdominal pain and bloating is more helpful than colonic transit time in classifying patient as IBS-C or FC.

Entities:  

Keywords:  Abdominal pain; Bloating; Constipation; Functional bowel disorders; Irritable bowel syndrome

Mesh:

Year:  2017        PMID: 28066860     DOI: 10.1007/s10151-016-1580-x

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  27 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 2.  Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?

Authors:  Dervla O'Malley; Eamonn M M Quigley; Timothy G Dinan; John F Cryan
Journal:  Brain Behav Immun       Date:  2011-04-23       Impact factor: 7.217

3.  Sacral nerve stimulation for the treatment of faecal incontinence related to dysfunction of the internal anal sphincter.

Authors:  Thomas C Dudding; David Parés; Carolynne J Vaizey; Michael A Kamm
Journal:  Int J Colorectal Dis       Date:  2010-02-02       Impact factor: 2.571

4.  Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls.

Authors:  Richard J Saad; Satish S C Rao; Kenneth L Koch; Braden Kuo; Henry P Parkman; Richard W McCallum; Michael D Sitrin; Gregory E Wilding; Jack R Semler; William D Chey
Journal:  Am J Gastroenterol       Date:  2009-11-03       Impact factor: 10.864

5.  Insights into normal and disordered bowel habits from bowel diaries.

Authors:  Adil E Bharucha; Barbara M Seide; Alan R Zinsmeister; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2007-11-16       Impact factor: 10.864

6.  Severe chronic constipation of young women: 'idiopathic slow transit constipation'.

Authors:  D M Preston; J E Lennard-Jones
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

7.  Importance of colonic transit evaluation in the management of fecal incontinence.

Authors:  Michel Bouchoucha; Ghislain Devroede; Alain Faye; Michel Arsac
Journal:  Int J Colorectal Dis       Date:  2002-09-04       Impact factor: 2.571

8.  Further characterization of painful constipation (PC): clinical features over one year and comparison with IBS.

Authors:  Douglas A Drossman; Carolyn Morris; Yuming Hu; Jane Leserman; Christine Dalton; Brenda Toner; Nicolas Diamante; Shrikant Bangdiwala
Journal:  J Clin Gastroenterol       Date:  2008 Nov-Dec       Impact factor: 3.062

9.  Differences between painless and painful constipation among community women.

Authors:  Adil E Bharucha; G Richard Locke; Alan R Zinsmeister; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2006-02-08       Impact factor: 10.864

10.  Physiologic study of the terminal digestive tract in chronic painful constipation.

Authors:  P Meunier
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

View more
  5 in total

1.  Influence of Age and Body Mass Index on Total and Segmental Colonic Transit Times in Constipated Subjects.

Authors:  Michel Bouchoucha; Marinos Fysekidis; Pierre Rompteaux; Gheorge Airinei; Jean-Marc Sabate; Robert Benamouzig
Journal:  J Neurogastroenterol Motil       Date:  2019-04-30       Impact factor: 4.924

Review 2.  Specific foods can reduce symptoms of irritable bowel syndrome and functional constipation: a review.

Authors:  Yohei Okawa; Shin Fukudo; Hiromi Sanada
Journal:  Biopsychosoc Med       Date:  2019-05-08

3.  A 5Ad Dietary Protocol for Functional Bowel Disorders.

Authors:  Fandi Ibrahim; Philippa Stribling
Journal:  Nutrients       Date:  2019-08-17       Impact factor: 5.717

Review 4.  Normative Values for Colonic Transit Time and Patient Assessment of Constipation in Adults With Functional Constipation: Systematic Review With Meta-Analysis.

Authors:  Larry E Miller; Alvin Ibarra; Arthur C Ouwehand
Journal:  Clin Med Insights Gastroenterol       Date:  2017-08-31

5.  Clinical Acupoint Selection for the Treatment of Functional Constipation by Massage and Acupuncture Based on Smart Medical Big Data Analysis.

Authors:  Fengzhi Sun; Zhuolin Liu; Wanli Zhang
Journal:  J Healthc Eng       Date:  2021-07-16       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.